{
  "Figure": "1-s2.0-S1556086415318475-main_page2_54.jpg",
  "Figure_title": "DISCUSSION Cetuximab monotherapy demonstrated no responses, a SD rate of 28%, and PFS of 1.8 months in a population of patients previously treated with EGFR TKI therapy. Of note, the patient population in this study was heavily pretreated, possibly biasing toward a lower likelihood of response to any additional therapy. Despite this, our results are fairly similar "
}